[March 11, 2014]

Research and Markets: Antibiotic Resistance Report: Market Developments, Growth Areas and Opportunities 2014

Research and Markets (http://www.researchandmarkets.com/research/qbfxdw/antibiotic) has announced the addition of the "Antibiotic Resistance: Market Developments, Growth Areas and Opportunities 2014" report to their offering.

This report provides a wealth of information for companies and Government departments working in this field, and through a detailed analysis of the study's findings, identifies commercial opportunities and provides insights, which will help to guide decision-making in this challenging field.

Threats posed by the global increase in antibiotic resistant bacterial strains continue to cause alarm, and some observers suggest that this problem is threatening to take societies back to a pre-antibiotic era. However, the last five years have seen important changes in practices, innovation and attitudes, in response to this growing threat. Biopharm Reports has recently carried out a global market study of antibiotic resistance, to identify the changing developments and management strategies that are taking place, and the opportunities these offer to developers i this field.

While the emergence of MRSA has embodied concerns over the rise of antibiotic resistance, other trends are becoming increasingly problematic. An example is the emergence of carbapenem resistance in K. pneumonia, due to a lack of alternative treatment options. Reports from the US suggest that 50-60% of all hospital-acquired infections are caused by antibiotic resistant bacteria, illustrating the human and financial impact of antibiotic resistance. In 2009, the World Health Organisation reported that in Europe 25,000 people die every year from drug-resistant infections. In the same year there were 440,000 new cases of MDR tuberculosis, in 69 countries.

A competitive market analysis of current practices and future developments across 25 key areas relating to antibiotic resistance.

Examples include:

- Diagnostics: Therapeutic areas, top Gram positives, Gram negatives and other pathogens; current and future development of companion diagnostics, tests to distinguish between bacterial and viral infections, the identification of causal bacterial pathogens, bacterial identification methods, preferred tests and instrumentation, preferred suppliers, integrated and antimicrobial stewardship programmes, requirements for innovation, new initiatives and barriers to success.

- Clinical: Therapeutic areas, top infection types, the major Gram positives, Gram negatives and other pathogens; distinguishing bacterial and viral infections, test costs and test times per patient, the identification of causal bacterial, preferred methods and suppliers, the identification of antibiotic resistance genes, integrated and antimicrobial stewardship programmes, requirements for innovation, new initiatives, barriers to success and future plans in these areas

- Suppliers: Who are the major company suppliers in the antibiotic resistance' market and who do diagnosticians and clinicians plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes are predicted in three years from now.

- Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the antibiotic resistance' market, in each of the 'Diagnostics', Clinical' and Laboratory' areas indicated below.

Background

For more information visit http://www.researchandmarkets.com/research/qbfxdw/antibiotic

[ Back To TMCnet.com's Homepage ]